Drug news
FDA Advisory Committee rejects nebivolol + valsartan combination for Hypertension- Forest/Actavis
Actavis plc has confirmed that the FDA Cardiovascular and Renal Drugs Advisory Committee (CRDAC) has voted to recommend against approval of Actavis' New Drug Application (NDA) for the fixed-dose combination of nebivolol and valsartan for the treatment of Hypertension. The committee vote was six to four recommending against approval.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
1 mins